Andrew G Gianoukakis

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
ORCID ORCID Icon0000-0002-8411-7059 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Gianoukakis is a Professor of Medicine; he joined the Internal Medicine faculty in 2002. Dr. Gianoukakis is the Program Director of The Harbor-UCLA Endocrinology Fellowship Program and current Chief of the Division of Endocrinology as well as APDEM past president (Association of Program Directors in Endocrinology and Metabolism). His special interest focuses on autoimmune thyroid disease, thyroid dysfunction and thyroid cancer. Dr. Gianoukakis is investigating molecular markers as a diagnostic tool in the Thyroid cancer. Dr. Gianoukakis is a member of ITOG (International Thyroid Oncology Group) and SCThyCC (Southern California Thyroid Cancer Consortium) and a Principal Investigator of clinical trials investigating the utility of small molecule kinase inhibitors for the treatment of advanced thyroid cancer. Dr. Gianoukakis is also the Course Chair of the HUCLA Endocrinology Elective Course, David Geffen School of Medicine at UCLA

    Collapse Research 
    Collapse Research Activities and Funding
    Thyrocytes Express Inflammatory Mediators
    NIH K23RR017304Jul 15, 2002 - Jun 30, 2008
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Sep 03; 30(17):3757-3767. French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. PMID: 38922338.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Influence of Thyroglobulin (Tg) Autoantibodies on Tg levels Measured by Different Methodologies: (IMA, LC-MS/MS and RIA). J Clin Endocrinol Metab. 2024 Apr 30. Petrovic I, LoPresti J, Fatemi S, Gianoukakis A, Burman K, Gomez-Lima CJ, Nguyen CT, Spencer CA. PMID: 38686504.
      View in: PubMed   Mentions:    Fields:    
    3. Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer. Eur Thyroid J. 2024 Feb 01; 13(1). Gianoukakis AG, Choe JH, Bowles DW, Brose MS, Wirth LJ, Owonikoko T, Babajanyan S, Worden FP. PMID: 38096102; PMCID: PMC10831529.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. Thyroglobulin Cutoff Values for Detecting Excellent Response to Therapy in Patients With Differentiated Thyroid Cancer. J Endocr Soc. 2023 Aug 01; 7(9):bvad102. Sipos JA, Aloi J, Gianoukakis A, Lee SL, Klopper JP, Kung JT, Lupo MA, Morgenstern D, Prat-Knoll C, Schuetzenmeister A, Goldner WS. PMID: 37564885; PMCID: PMC10410295.
      View in: PubMed   Mentions: 2  
    5. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 02; 12(4):4332-4342. Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. PMID: 36464853; PMCID: PMC9972135.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    6. An Assessment of Diversity, Inclusion, and Health Equity Training in Endocrinology Fellowship Programs in the United States. Endocr Pract. 2022 Nov; 28(11):1159-1165. Malek R, Shibli-Rahhal A, Correa R, Szmuilowicz ED, Morgan F, Luthra P, Sirisena I, Gianoukakis A, Smooke Praw S, Lieb DC, Haw JS, Mayson SE. PMID: 35985561.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). J Clin Oncol. 2022 06 10; 40(17):1870-1878. Ho AL, Dedecjus M, Wirth LJ, Tuttle RM, Inabnet WB, Tennvall J, Vaisman F, Bastholt L, Gianoukakis AG, Rodien P, Paschke R, Elisei R, Viola D, So K, Carroll D, Hovey T, Thakre B, Fagin JA, ASTRA investigator group. PMID: 35192411; PMCID: PMC9851689.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    8. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022 02 17; 107(3):776-787. Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. PMID: 34664662; PMCID: PMC8852210.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    9. Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer. Endocrine. 2022 05; 76(2):491-494. Gouda MA, Ong E, Huang HJ, McPhaul LW, Yoon S, Janku F, Gianoukakis AG. PMID: 35152349.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Graves' disease patients with iron deficiency anemia: serologic evidence of co-existent autoimmune gastritis. Am J Blood Res. 2021; 11(3):238-247. Gianoukakis AG, Gupta S, Tran TN, Richards P, Yehuda M, Tomassetti SE. PMID: 34322286; PMCID: PMC8303011.
      View in: PubMed   Mentions: 1  
    11. Response to Rosário and Souza Côrtes re: "The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence". Thyroid. 2020 11; 30(11):1686-1687. Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG. PMID: 32484055.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence. Thyroid. 2020 10; 30(10):1490-1495. Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG, National Thyroid Cancer Treatment Cooperative Study Group. PMID: 32228151; PMCID: PMC7869880.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Voluntary Adoption of an All In Match Policy in the Medical Specialties Matching Program: Advantages and Disadvantages. J Grad Med Educ. 2019 08; 11(4):378-381. McCartney CR, Gianoukakis AG, Gopalakrishnan G, McGill JB, Roach P, Siraj ES, True MW. PMID: 31440329; PMCID: PMC6699534.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy. Endocrinol Diabetes Metab J. 2019 Feb; 3(1). Zimering MB, Shin JJ, Zaitz JD, Nunez EA, Gianoukakis AG. PMID: 30854171; PMCID: PMC6407713.
      View in: PubMed   Mentions:
    15. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019 01; 106:61-68. Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A. PMID: 30471649.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    16. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer. 2018 06; 25(6):699-704. Gianoukakis AG, Dutcus CE, Batty N, Guo M, Baig M. PMID: 29752332; PMCID: PMC5958278.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    17. Parity and Risk of Thyroid Autoimmunity Based on the NHANES (2001-2002, 2007-2008, 2009-2010, and 2011-2012). J Clin Endocrinol Metab. 2017 09 01; 102(9):3437-3442. Yehuda M, Wang CH, Pak Y, Chiu KC, Gianoukakis AG. PMID: 28911140.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    18. Thymic Hyperplasia Associated with Graves' Disease: Pathophysiology and Proposed Management Algorithm. Thyroid. 2017 08; 27(8):994-1000. Haider U, Richards P, Gianoukakis AG. PMID: 28578595.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    19. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. PMID: 28155175; PMCID: PMC5368192.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    20. A Cervical Schwannoma Masquerading as a Thyroid Nodule. Eur Thyroid J. 2017 Jul; 6(4):216-220. Nagavalli S, Yehuda M, McPhaul LW, Gianoukakis AG. PMID: 28868262; PMCID: PMC5566684.
      View in: PubMed   Mentions: 6     Fields:    
    21. Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer. Cancer Manag Res. 2016; 8:67-76. Gianoukakis AG, Flores NM, Pelletier CL, Forsythe A, Wolfe GR, Taylor MH. PMID: 27313476; PMCID: PMC4892292.
      View in: PubMed   Mentions: 2  
    22. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12; 372(7):621-30. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. PMID: 25671254.
      View in: PubMed   Mentions: 762     Fields:    Translation:HumansCTClinical Trials
    23. Thyroglobulin antibody status and differentiated thyroid cancer: what does it mean for prognosis and surveillance? Curr Opin Oncol. 2015 Jan; 27(1):26-32. Gianoukakis AG. PMID: 25390556.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    24. Treatment Patterns and Health Outcomes Among Patients with Radioiodine-Refractory Differentiated Thyroid Cancer in the United States and Western Europe. Value Health. 2014 Nov; 17(7):A614. Gianoukakis AG, Flores NM, Pelletier CL, DiBonaventura M, Forsythe A, Wolfe G, Rege J, Taylor MH. PMID: 27202148.
      View in: PubMed   Mentions: 1     Fields:    
    25. Computer modeling of a newly identified THRB gene mutation (S350L) associated with resistance to thyroid hormone in three unrelated patients. Thyroid. 2014 Sep; 24(9):1430-1. Nagavalli S, Fletterick RJ, Ford G, Boston BA, Gianoukakis AG. PMID: 24906004; PMCID: PMC4361411.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Familial adenomatous polyposis-associated, cribriform morular variant of papillary thyroid carcinoma harboring a K-RAS mutation: case presentation and review of molecular mechanisms. Thyroid. 2014 Jul; 24(7):1184-9. Giannelli SM, McPhaul L, Nakamoto J, Gianoukakis AG. PMID: 24702198.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    27. Elephantiatic dermopathy. Int J Dermatol. 2013 Aug; 52(8):987-9. Madaj P, McPhaul L, Gianoukakis AG. PMID: 22417118; PMCID: PMC4334560.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Visual vignette. Neurocysticercosis. Endocr Pract. 2011 Nov-Dec; 17(6):965. Munir I, Qing X, Mlikotic A, Gianoukakis AG. PMID: 21803719.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease. J Clin Endocrinol Metab. 2011 Dec; 96(12):3827-37. Smith TJ, Padovani-Claudio DA, Lu Y, Raychaudhuri N, Fernando R, Atkins S, Gillespie EF, Gianoukakis AG, Miller BS, Gauger PG, Doherty GM, Douglas RS. PMID: 21956421; PMCID: PMC3232631.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    30. Management of severe thyrotoxicosis when the gastrointestinal tract is compromised. Thyroid. 2011 Mar; 21(3):215-20. Alfadhli E, Gianoukakis AG. PMID: 21254909.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    31. Pancreatic neuroendocrine tumors. Endocr Res. 2011; 36(1):35-43. Batcher E, Madaj P, Gianoukakis AG. PMID: 21226566.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    32. Update in thyroidology 2010. J Clin Endocrinol Metab. 2011 Jan; 96(1):9-14. Hershman JM, Cheng SY, Gianoukakis AG. PMID: 21209040.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. Well differentiated follicular thyroid neoplasia: impact of molecular and technological advances on detection, monitoring and treatment. Mol Cell Endocrinol. 2011 Jan 30; 332(1-2):9-20. Gianoukakis AG, Giannelli SM, Salameh WA, McPhaul LW. PMID: 21094678.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    34. Visual vignette. Endocr Pract. 2010 Nov-Dec; 16(6):1081. Madaj P, Tran T, Varma R, Gianoukakis AG. PMID: 20713335.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Familial thyroid neoplasia: impact of technological advances on detection and monitoring. Curr Opin Endocrinol Diabetes Obes. 2010 Oct; 17(5):425-31. Tran T, Gianoukakis AG. PMID: 20729730.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010 Jan; 95(1):430-8. Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, Gianoukakis AG, Smith TJ. PMID: 19897675; PMCID: PMC2805489.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCells
    37. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008 Oct 15; 181(8):5768-74. Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, Kamat S, Smith TJ. PMID: 18832736; PMCID: PMC2562248.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    38. Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2008 Oct; 15(5):446-52. Gianoukakis AG, Smith TJ. PMID: 18769218; PMCID: PMC3712753.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    39. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol. 2008 Sep 15; 181(6):4397-405. Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ. PMID: 18768899; PMCID: PMC2775538.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansCells
    40. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008 Sep; 18(9):983-8. Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG. PMID: 18788919; PMCID: PMC2574420.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    41. Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. Thyroid. 2008 Sep; 18(9):953-8. Gianoukakis AG, Khadavi N, Smith TJ. PMID: 18713026; PMCID: PMC2879490.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    42. Characterization of the anaemia associated with Graves' disease. Clin Endocrinol (Oxf). 2009 May; 70(5):781-7. Gianoukakis AG, Leigh MJ, Richards P, Christenson PD, Hakimian A, Fu P, Niihara Y, Smith TJ. PMID: 18710465; PMCID: PMC3712752.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    43. Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes. Clin Exp Immunol. 2007 Apr; 148(1):64-71. Douglas RS, Gianoukakis AG, Goldberg RA, Kamat S, Smith TJ. PMID: 17349012; PMCID: PMC1868859.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    44. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol. 2007 Mar 01; 178(5):3281-7. Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. PMID: 17312178.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCellsCTClinical Trials
    45. Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts. Endocrinology. 2007 Jan; 148(1):54-62. Gianoukakis AG, Jennings TA, King CS, Sheehan CE, Hoa N, Heldin P, Smith TJ. PMID: 17068136.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    46. Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways. J Immunol. 2006 Apr 15; 176(8):5084-92. Gilbert JA, Gianoukakis AG, Salehi S, Moorhead J, Rao PV, Khan MZ, McGregor AM, Smith TJ, Banga JP. PMID: 16585606.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    47. Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology. 2006 Apr; 147(4):1941-9. Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, Smith TJ. PMID: 16410300.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    48. Cytokine-induced lymphocyte chemoattraction from cultured human thyrocytes: evidence for interleukin-16 and regulated upon activation, normal T cell expressed, and secreted expression. Endocrinology. 2003 Jul; 144(7):2856-64. Gianoukakis AG, Martino LJ, Horst N, Cruikshank WW, Smith TJ. PMID: 12810540.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    49. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun. 2003 May; 24(5):489-95. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. PMID: 12717064.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    50. Autonomous thyroid nodules visualized by positron emission tomography with 18F-fluorodeoxyglucose: a case report and review of the literature. Thyroid. 2003 Apr; 13(4):395-9. Gianoukakis AG, Karam M, Cheema A, Cooper JA. PMID: 12804108.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Ritonavir-associated hyperparathyroidism, osteopenia and bone pain. AIDS. 2002 Jul 26; 16(11):1565-6. Piliero PJ, Gianoukakis AG. PMID: 12131200.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    52. Prostaglandin endoperoxide H synthase expression in human thyroid epithelial cells. Am J Physiol Cell Physiol. 2001 Mar; 280(3):C701-8. Gianoukakis AG, Cao HJ, Jennings TA, Smith TJ. PMID: 11171589.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    53. Comparison of diabetes care provided by an endocrinology clinic and a primary-care clinic. Endocr Pract. 2000 Sep-Oct; 6(5):361-6. Leinung MC, Gianoukakis AG, Lee DW, Jeronis SL, Desemone J. PMID: 11141586.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    Andrew's Networks
    Concepts (274)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California